CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants.

On April 30, 2026, as an inducement material to acceptance of employment with CareDx, 23 new employees were awarded restricted stock units (RSUs) for an aggregate of 63,856 shares of common stock.

The RSU awards were made pursuant to the Company’s 2019 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years, with 25% of the RSUs vesting on the first anniversary of each employee’s vesting commencement date, and 1/16th of the RSUs vesting on each date that is three (3) months thereafter subject to each employee’s continued service through each vesting date.

CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260501877613/en/

CareDx
Media Contacts
Natasha Moshirian Wagner
[email protected]

Investor Relations
Caroline Corner
[email protected]

Source: CareDx, Inc.

You May Also Be Interested In

• Faraday Future Unveils Its Second-Half Launch of the FF EAI Robot World, Including the Launch of Its New Mobile Manipulator, the All-New Futurist, and a Preview of FF’s EAI Robotics Industrial Ecosy
• Carol Anne Mills Expands Video First Real Estate Marketing Program Following Multiple South Bay Home Sales Above Asking Price
• Lynn Ross Support & Growth Announces Expanded Grief Recovery Support to Help Individuals Navigate Loss Through the Evidence Based Grief Recovery Method